StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Rachna Vaidya

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byRachna VaidyaHorizon: BTST11 Aug 2026, 3:14 pm ISTvia CNBC Awaaz.

Entry₹1,191Inferred
Target₹1,210
Total upside +1.60% (call closed)
Stop loss₹1,185-0.50% risk
Exit₹1,18512 Aug 2026, 9:15 am
Stop-loss hit-0.50%
Follow Rachna Vaidya for new calls(12% target hit, 42 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 3 active BTST picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 12 Aug 2026
6 supporting5 neutral1 opposing
Supports the BUY call (6)

Zydus Lifesciences Limited's subsidiary, Sentynl Therapeutics, has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Defic

NSE · Press Release·11 Aug · today

(opens in new tab)

Zydus Lifesciences' subsidiary Sentynl Therapeutics has entered into an option and license agreement with Mereo BioPharma for alvelestat, a potential treatment for Alpha-1 Antitrypsin Deficiency-Assoc

BSE · Company Update·11 Aug · today

(opens in new tab)

Zydus Lifesciences Q1 Results: Stock jumps over 6%; India biz leads growth

NewsCnbc-Tv18·11 Aug · today

(opens in new tab)

Macquarie Hikes Zydus Lifesciences' Target Ahead Of Q1 Results; Bets On New Business Buildout To Drive Growth

NewsNdtv-Profit·11 Aug · yesterday

(opens in new tab)

Zydus Lifesciences Ltd has launched REVAHALE, which is India's first once-daily nebulised LAMA medication for COPD.

BSE · Company Update·10 Aug · yesterday

(opens in new tab)
Neutral / worth noting (5)

Zydus Lifesciences Limited has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026. The filing is a disclosure under SEBI regulations.

NSE · Press Release·11 Aug · today

(opens in new tab)

Zydus Lifesciences Ltd has submitted a press release regarding its unaudited financial results for the quarter ended June 30, 2026, as per SEBI regulations.

BSE · Company Update·11 Aug · today

(opens in new tab)

Unaudited financial results for the quarter ended on June 30, 2026

BSE · Board Meeting·11 Aug · today

(opens in new tab)

Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price

NewsNdtv-Profit·11 Aug · yesterday

(opens in new tab)

Market Pulse: Key triggers to watch before the August 11 trading session

NewsCnbc-Tv18·10 Aug · yesterday

(opens in new tab)
Weighs against the BUY call (1)

Zydus Lifesciences Q1 Results: Net profit down 36% at Rs 939.8 crore

NewsEt-Markets·11 Aug · today

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Rachna Vaidya

Every call and its outcome